Effect of p53 activation through targeting MDM2/MDM4 heterodimer on T regulatory and effector cells in the peripheral blood of Type 1 diabetes patients
Fig 3
Frequency of T cell populations in PBMC isolated from type 1 diabetes patients treated with peptide 3 and subsequently stimulated with anti-CD3/CD28 beads for 4 days.
Flow-cytometry analysis of type 1 diabetes PBMC non-treated non-stimulated (RPMI) or stimulated (anti-CD3/CD28), treated with 15μM Pep3 and subsequently stimulated with anti-CD3/CD28 beads for four days. Percentages were obtained as described for the previous experiments (see legend to Fig 1). Graphs show the percentage of CD8+ Treg as CD8+ CD25+FOXP3+ cells (a), CD8+ Teff as CD8+ CD25-FOXP3- cells (b), CD8+ Treg/Teff ratio (c), CD8+ Teff activated cells as CD8+ CD25+FOXP3- cells (d), CD4+ Treg as CD4+ CD25+FOXP3+ cells (e), CD4+ Teff as CD4+ CD25-FOXP3- cells (f), CD4+ Treg/Teff ratio (g), CD4+ Teff activated cells as CD4+ CD25+FOXP3- cells (h). Values correspond to mean frequency ± SEM of 16 LT type 1 diabetes patients. ** p<0.01, *** p<0.001, **** p<0.0001.